載入中
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
一般交易時段
US$1.355
−US$0.125 · -8.45%
盤中時間採用ET。市場資料可能有所延遲。
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
日內區間
目前US$1.355
52週區間
目前US$1.355
盤中時間採用ET。市場資料可能有所延遲。
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
日內區間
目前US$1.355
52週區間
目前US$1.355
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.42萬 USD | 256.68萬 USD | 284.18萬 USD | 672.21萬 USD | — |
| 銷貨成本 | 4.34萬 USD | 160.74萬 USD | 228.14萬 USD | 413.57萬 USD | — |
| 毛利 | 1.08萬 USD | 95.94萬 USD | 56.04萬 USD | 258.64萬 USD | — |
| 研究與開發 | 544.29萬 USD | 638.9萬 USD | 767.63萬 USD | 933.84萬 USD | 817.36萬 USD |
| 銷售、一般及管理費用 | 770.13萬 USD | 2194.52萬 USD | 1308.44萬 USD | 798.83萬 USD | 530.22萬 USD |
| 營業費用 | 1126.81萬 USD | 3043.91萬 USD | 2627.75萬 USD | 1766.52萬 USD | 1336.78萬 USD |
| 利息收入 | — | — | — | — | 50.54萬 USD |
| 利息支出 | 125.03萬 USD | 115.84萬 USD | 28.3萬 USD | 12.67萬 USD | — |
| 折舊和攤銷 | 104.18萬 USD | 118.44萬 USD | 113.52萬 USD | 71.79萬 USD | 54.36萬 USD |
| 營業利益 | −1125.73萬 USD | −2947.97萬 USD | −2571.72萬 USD | −1507.88萬 USD | −1336.78萬 USD |
| 淨利 | −795.97萬 USD | −3002.38萬 USD | −2499.43萬 USD | −1490.07萬 USD | −1286.25萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
